FXI Launch Not Taking NFTRH Subscribers by Surprise

While featuring good calls that I have failed to personally take advantage of (can’t buy everything and my focus has been on Biotech and Specialty Pharma for available risk funds), here is another one.  Using the associated index FXT, we have been chronicling the China 25’s attempted and actualized breakout for months now. Also, last week NFTRH 337 included a chart of FXT vs. SPX … Continue reading FXI Launch Not Taking NFTRH Subscribers by Surprise